GTXI stock forecast
Our latest prediction for GTx, Inc.'s stock price was made on the Jan. 5, 2018 when the stock price was at 11.07$.
In the short term (2weeks), GTXI's stock price should underperform the market by -0.34%. During that period the price should oscillate between -9.15% and +19.16%.
In the medium term (3months), GTXI's stock price should outperform the market by 5.66%. During that period the price should oscillate between -21.54% and +40.07%.Get email alerts
Create a solid portfolio with GTXI
About GTx, Inc.
GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.86$ per share.
The book value per share is 1.66$
Three months stock forecastJan. 5, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|